Sex steroids and vascular responses in hypertension and aging

Gender Medicine

Volumn 5, Issue SUPPL. 1, 2008, Pages

  Qiao, Xiaoying ^a   McConnell, Kristi R ^a   Khalil, Raouf A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

blood vessels; calcium; endothelium; estrogen; menopause; nitric oxide; progesterone; testosterone; vascular smooth muscle

Indexed keywords

C REACTIVE PROTEIN; CALCIUM ION; CONJUGATED ESTROGEN; DAIDZEIN; EQUOL; ESTRADIOL; ESTROGEN; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; GENISTEIN; GESTAGEN; HORMONE; HORMONE RECEPTOR; IDOXIFENE; MEDROXYPROGESTERONE ACETATE; NITRIC OXIDE; PHYTOESTROGEN; PRASTERONE; PROGESTERONE; PROSTACYCLIN; PROTEIN KINASE C; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; TAMOXIFEN; TESTOSTERONE;

AGING; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; BREAST CANCER; BREAST TENDERNESS; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG DOSE COMPARISON; ENDOTHELIUM CELL; GENETIC POLYMORPHISM; HORMONAL THERAPY; HUMAN; HYPERPOLARIZATION; HYPERTENSION; LOW DRUG DOSE; MEDLINE; MONOTHERAPY; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RISK REDUCTION; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; TESTOSTERONE BLOOD LEVEL; VAGINA BLEEDING; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION; VENOUS THROMBOEMBOLISM;

AGING; ANIMALS; CALCIUM; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; HYPERTENSION; MUSCLE CONTRACTION; NITRIC OXIDE; PROTEIN KINASE C; RECEPTORS, ESTROGEN;

EID: 41449115538     PISSN: 15508579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genm.2008.03.006     Document Type: Article

References (111)

1. Koledova V., and Khalil R. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease. Expert Rev Cardiovasc Ther 55 (2007) 777-789
2. Stampfer M., Colditz G., Willett W., et al. Post-menopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 3325 (1991) 756-762
3. Grady D., Rubin S., Petitti D., et al. Hormone therapy to prevent disease and prolong life in post-menopausal women. Ann Intern Med 1117 (1992) 1016-1037
4. Rosano G., Sarrel P., Poole Wilson P., and Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 3342 (1993) 133-136
5. Grodstein F., Stampfer M., Manson J., et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease [published correction appears in N Engl J Med. 1996;3335:1406]. N Engl J Med 335 (1996) 453-461
6. Barrett-Connor E., and Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 119 (1998) 55-72
7. Orshal J., and Khalil R. Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol 286 (2004) R233-R249
8. Hulley S., Grady D., Bush T., et al., for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for the secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
9. Manson J., Hsia J., Johnson K., et al., for the Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 (2003) 523-534
10. Hsia J., Langer R., Manson J., et al., for the Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: The Women's Health Initiative [published correction appears in Arch Intern Med. 2006;1166:759]. Arch Intern Med. 166 (2006) 357-365
11. Masi C., Hawkley L., Berry J., and Cacioppo J. Estrogen metabolites and systolic blood pressure in a population-based sample of postmenopausal women. J Clin Endocrinol Metab 91 (2006) 1015-1020
12. Hu P., Greendale G., Palla S., et al. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: The postmenopausal estrogen progestin intervention (PEPI) trial. Atherosclerosis 185 (2006) 347-352
13. Cruz M., Agewall S., Schenck--Gustafsson K., and Kublickiene K. Acute dilatation to phytoestrogens and estrogen receptor subtypes expression in small arteries from women with coronary heart disease. Atherosclerosis 196 (2008) 49-58
14. Bolego C., Vegeto E., Pinna C., et al. Selective agonists of estrogen receptor isoforms: New perspectives for cardiovascular disease. Arterioscler Thromb Vasc Biol 26 (2006) 2192-2199
15. Cummings S., Eckert S., Krueger K., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE Randomized Trial. Multiple Outcomes of Raloxifene Evaluation [published correction appears in JAMA. 1999;282:2124]. JAMA 281 (1999) 2189-2197
16. Freedman A., Graubard B., Rao S., et al. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 95 (2003) 526-532
17. Vogel V., Costantino J., Wickerham D., et al., for the National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295 (2006) 2727-2741
18. Frasor J., Chang E., Komm B., et al. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 66 (2006) 7334-7340
19. Somjen D., Katzburg S., Knoll E., et al. DT56a (Femarelle): A natural selective estrogen receptor modulator (SERM). J Steroid Biochem Mol Biol 104 (2007) 252-258
20. Mosca L., Barrett--Connor E., Wenger N., et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 88 (2001) 392-395
21. Barrett-Connor E., Mosca L., Collins P., et al., for the Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355 (2006) 125-137
22. Herrington D., Reboussin D., Klein K., et al. The estrogen replacement and atherosclerosis (ERA) study: Study design and baseline characteristics of the cohort [published correction appears in Control Clin Trials. 2000;21:414]. Control Clin Trials 21 (2000) 257-285
23. Harman S., Brinton E., Cedars M., et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 8 (2005) 3-12
24. Ettinger B. Rationale for use of lower estrogen doses for postmenopausal hormone therapy. Maturitas 57 (2007) 81-84
25. Ho J., Chen M., Sheu W., et al. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Hum Reprod 21 (2006) 2715-2720
26. Persico N., Mancini F., Artini P., et al. Transdermal HRT and Doppler findings in normotensive and hypertensive postmenopausal patients. Ultrasound Obstet Gynecol 26 (2005) 546-551
27. Lyytinen H., Pukkala E., and Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 108 (2006) 1354-1360
28. Fugh-Berman A., and Bythrow J. Bioidentical hormones for menopausal hormone therapy: Variation on a theme. J Gen Intern Med 22 (2007) 1030-1034
29. Panjari M., and Davis S. DHEA therapy for women: Effect on sexual function and wellbeing. Hum Reprod Update 13 (2007) 239-248
30. Mendelsohn M. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol 90 (2002) 3F-6F
31. Zhu Y., Bian Z., Lu P., et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 295 (2002) 505-508
32. Mendelsohn M., and Karas R. Molecular and cellular basis of cardiovascular gender differences. Science 308 (2005) 1583-1587
33. Revankar C., Cimino D., Sklar L., et al. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307 (2005) 1625-1630
34. Thomas P., Pang Y., Filardo E., and Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146 (2005) 624-632
35. Haas E., Meyer M., Schurr U., et al. Differential effects of 17Beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension 449 (2007) 1358-1363
36. Figtree G., McDonald D., Watkins H., and Channon K. Truncated estrogen receptor alpha 46-kDa isoform in human endothelial cells: Relationship to acute activation of nitric oxide synthase. Circulation 107 (2003) 120-126
37. Flouriot G., Griffin C., Kenealy M., et al. Differentially expressed messenger RNA isoforms of the human estrogen receptor-alpha gene are generated by alternative splicing and promoter usage. Mol Endocrinol 12 (1998) 1939-1954
38. Reimann M., Vafeiadou K., Hall W., et al. Evidence for associations between common polymorphisms of estrogen receptor beta gene with homocysteine and nitric oxide. Climacteric 9 (2006) 215-223
39. Zhai P., Eurell T., Cooke P., et al. Myocardial ischemia-reperfusion injury in estrogen receptor-alpha knockout and wild-type mice. Am J Physiol Heart Circ Physiol 278 (2000) H1640-H1647
40. Wang M., Crisostomo P., Wairiuko G., and Meldrum D. Estrogen receptor-alpha mediates acute myocardial protection in females. Am J Physiol Heart Circ Physiol 290 (2006) H2204-H2209
41. O'Lone R., Knorr K., Jaffe I., et al. Estrogen receptors alpha and beta mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen species. Mol Endocrinol 21 (2007) 1281-1296
42. Leung S., Teoh H., Keung W., and Man R. Nongenomic vascular actions of female sex hormones: Physilogical implications and signalling pathways. Clin Exp Pharmacol Physiol 34 (2007) 822-826
43. Wynne F., and Khalil R. Testosterone and coronary vascular tone: Implications in coronary artery disease. J Endocrinol Invest 26 (2003) 181-186
44. Chen Z., Yuhanna I., Galcheva--Gargova Z., et al. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen [published correction appears in J Clin Invest. 1999;103:1363 ]. J Clin Invest 103 (1999) 401-406
45. Pare G., Krust A., Karas R., et al. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 90 (2002) 1087-1092
46. Darblade B., Pendaries C., Krust A., et al. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circ Res 90 (2002) 413-419
47. Nilsson B., Ekblad E., Heine T., and Gustafsson J. Increased magnitude of relaxation to oestrogen in aorta from oestrogen receptor beta knock-out mice. J Endocrinol 166 (2000) R5-R9
48. Widder J., Pelzer T., von Poser--Klein C., et al. Improvement of endothelial dysfunction by selective estrogen receptor-alpha stimulation in ovariectomized SHR. Hypertension 442 (2003) 991-996
49. Chambliss K., Yuhanna I., Anderson R., et al. ERbeta has nongenomic action in caveolae. Mol Endocrinol 16 (2002) 938-946
50. McCarty M. Isoflavones made simple-genistein's agonist activity for the beta-type estrogen receptor mediates their health benefits. Med Hypotheses 66 (2006) 1093-1114
51. Forte P., Kneale B., Milne E., et al. Evidence for a difference in nitric oxide biosynthesis between healthy women and men. Hypertension 32 (1998) 730-734
52. 2+-independent activation of endothelial nitric-oxide synthase/Hsp90 involving ERK1/22 and Akt phosphorylatio on in human endothelial cells. J Biol Chem 281 (2006) 27335-27345
53. Haynes M., Sinha D., Russell K., et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the P13-kinase-Akt pathway in human endothelial cells. Circ Res 87 (2000) 677-682
54. Simoncini T., Fornari L., Mannella P., et al. Differential estrogen signaling in endothelial cells upon pulsed or continuous administration. Maturitas 50 (2005) 247-258
55. Chan Y., Leung F., Yao X., et al. Raloxifene modulates pulmonary vascular reactivity in spontaneously hypertensive rats. J Cardiovasc Pharmacol 49 (2007) 355-361
56. Leung H., Yung L., Leung F., et al. Tamoxifen dilates porcine coronary arteries: Roles for nitric oxide and ouabain-sensitive mechanisms. Br J Pharmacol 149 (2006) 703-711
57. Hernandez I., Delgado J., Diaz J., et al. 17Beta-estradiol prevents oxidative stress and decreases blood pressure in ovariectomized rats. Am J Physiol Regul Integr Comp Physiol 279 (2000) R1599-R1605
58. Traupe T., Stettler C., Li H., et al. Distinct roles of estrogen receptors alpha and beta mediating acute vasodilation of epicardial coronary arteries. Hypertension 49 (2007) 1364-1370
59. Zhang P., Li H., Tian Z., et al. Effects of phytoestrogens and 17Beta-estradiol on vasoconstriction elicited by reactive oxygen species. Pharmazie 62 (2007) 378-381
60. Siow R., Li F., Rowlands D., et al. Cardiovascular targets for estrogens and phytoestrogens: Transcriptional regulation of nitric oxide synthase and antioxidant defense genes. Free Radic Biol Med 42 (2007) 909-925
61. Barber D., and Miller V. Gender differences in endothelium-dependent relaxations do not involve NO in porcine coronary arteries. Am J Physiol 273 (1997) H2325-H2332
62. Egan K., Lawson J., Fries S., et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306 (2004) 1954-1957
63. Han G., Ma H., Chintala R., et al. Nongenomic, endothelium-independent effects of estrogen on human coronary smooth muscle are mediated by type I (neuronal) NOS and P13-kinase-Akt signaling. Am J Physiol Heart Circ Physiol 293 (2007) H314-H321
64. Bilsel A., Moini H., Tetik E., et al. 17Beta-estradiol modulates endothelin-1 expression and release in human endothelial cells. Cardiovasc Res 46 (2000) 579-584
65. Dubey R., Jackson E., Keller P., et al. Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension 37 (2001) 640-644
66. David F., Carvalho M., Cobra A., et al. Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats. Hypertension 38 (2001) 692-696
67. Methot J., Hamelin B., Arsenault M., et al. The ACEDD genotype is associated with endothelial dysfunction in postmenopausal women. Menopause 13 (2006) 959-966
68. Lewis D., Avsar M., Labreche P., et al. Treatment with raloxifene and 17Beta-estradiol differentially modulates nitric oxide and prostanoids in venous endothelium and platelets of ovariectomized pigs. J Cardiovasc Pharmacol 48 (2006) 231-238
69. Bayram M., Bayram O., Karadeniz Bilgili M., et al. Evaluation of hormone replacement therapy which may have an adrenomedullin-mediated protective effect on cardiovascular disorders. Aging Clin Exp Res 19 (2007) 224-227
70. Wassmann K., Wassmann S., and Nickenig G. Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function. Circ Res 97 (2005) 1046-1054
71. Sunday L., Tran M., Krause D., and Duckles S. Estrogen and progestagens differentially modulate vascular proinflammatory factors. Am J Physiol Endocrinol Metab 291 (2006) E261-E267
72. Register T., Adams M., Golden D., and Clarkson T. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol 18 (1998) 1164-1171
73. Adams M., Register T., Golden D., et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 17 (1997) 217-221
74. Vicent G., Ballare C., Zaurin R., et al. Chromatin remodeling and control of cell proliferation by progestins via cross talk of progesterone receptor with the estrogen receptors and kinase signaling pathways. Ann N Y Acad Sci 1089 (2006) 59-72
75. Zerr--Fouineau M., Chataigneau M., Blot C., and Schini-Kerth V. Progestins overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelial NO synthase via glucocorticoid receptors. FASEB J 21 (2007) 265-273
76. Preston R., Norris P., Alonso A., et al. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause 14 (2007) 408-414
77. Simoncini T., Fu X., Caruso A., et al. Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors. Hum Reprod 22 (2007) 2325-2334
78. 2+ entry mechanisms of coronary vasoconstriction. Arterioscler Thromb Vasc Biol 19 (1999) 1034-1040
79. Ding A., and Stallone J. Testosterone-induced relaxation of rat aorta is androgen structure specific and involves K+ channel activation. J Appl Physiol 91 (2001) 2742-2750
80. Norata G., Tibolla G., Seccomandi P., et al. Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells. J Clin Endocrinol Metab 91 (2006) 546-554
81. Xiang Q., Chen Y., Lin G., et al. Effects of selective estrogen receptor modulator raloxifene plus 17-beta estradiol in aorta and mammary gland of female experimental atherosclerosis rabbits and possible involvement of ERK signal transduction pathway. Chin J Physiol 49 (2006) 132-140
82. Khalil R., and van Breemen C. Intracellular free calcium concentration/force relationship in rabbit inferior vena cava activated by norepinephrine and high K+. Pflugers Arch 416 (1990) 727-734
83. Salamanca D., and Khalil R. Protein kinase C isoforms as specific targets for modulation of vascular smooth muscle function in hypertension. Biochem Pharmacol 70 (2005) 1537-1547
84. 2+ entry mechanisms of arterial vasoconstriction by sex hormones. Clin Exp Pharmacol Physiol 26 (1999) 707-715
85. Nickenig G., Strehlow K., Wassmann S., et al. Differential effects of estrogen and progesterone on AT(1) receptor gene expression in vascular smooth muscle cells. Circulation 102 (2000) 1828-1833
86. Dean S., Tan J., O'Brien E., and Leenen F. 17Beta-estradiol downregulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats. Am J Physiol Regul Integr Comp Physiol 288 (2005) R759-R766
87. Smith A., Jones R., and Channer K. The influence of sex hormones on pulmonary vascular reactivity: Possible vasodilator therapies for the treatment of pulmonary hypertension. Curr Vasc Pharmacol 4 (2006) 9-15
88. i during inhibition of coronary smooth muscle contraction by 17Beta-estradiol, progesterone, and testosterone. J Pharmacol Exp Ther 291 (1999) 44-52
89. 2+ currents in A7r5 vascular smooth muscle cell line. Am J Physiol 266 (1994) C975-C980
90. Rosano G., Collins P., Gerbara O., et al. Effect of estradiol 17beta upon coronary artery vasoconstrictor response to methylergometrine maleate in female menopausal patients. Int J Cardiol 107 (2006) 254-259
91. Li H., Zhang P., Tian Z., et al. Differential mechanisms involved in effects of genistein and 17-beta-estradiol on porcine coronary arteries. Pharmazie 61 (2006) 461-465
92. Mishra R., Stanczyk F., Burry K., et al. Metabolite ligands of estrogen receptor-beta reduce primate coronary hyperreactivity. Am J Physiol Heart Circ Physiol 290 (2006) H295-H303
93. Honda H., Unemoto T., and Kogo H. Different mechanisms for testosterone-induced relaxation of aorta between normotensive and spontaneously hypertensive rats. Hypertension 34 (1999) 1232-1236
94. Arias-Loza P., Hu K., Dienesch C., et al. Both estrogen receptor subtypes, alpha and beta, attenuate cardiovascular remodeling in aldosterone salt-treated rats. Hypertension 50 (2007) 432-438
95. i in vascular smooth muscle cells of female rat. Am J Physiol Cell Physiol 278 (2000) C834-C844
96. Garcia P., Gimenez J., Bonacasa B., et al. 17Beta-estradiol exerts a beneficial effect on coronary vascular remodeling in the early stages of hypertension in spontaneously hypertensive rats. Menopause 12 (2005) 453-459
97. Kanashiro C., and Khalil R. Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. Am J Physiol Cell Physiol 280 (2001) C34-C45
98. Minshall R., Pavcnik D., Browne D., and Hermsmeyer K. Nongenomic vasodilator action of progesterone on primate coronary arteries. J Appl Physiol 92 (2002) 701-708
99. Fortepiani L., Zhang H., Racusen L., et al. Characterization of an animal model of postmenopausal hypertension in spontaneously hypertensive rats. Hypertension 41 (2003) 640-645
100. Payne J., Reckelhoff J., and Khalil R. Role of oxidative stress in age-related reduction of NO-cGMP mediated vascular relaxation in SHR. Am J Physiol Regul Integr Comp Physiol 285 (2003) R542-R551
101. Wynne F., Payne J., Cain A., et al. Age-related reduction in estrogen receptor-mediated mechanisms of vascular relaxation in female spontaneously hypertensive rats. Hypertension 43 (2004) 405-412
102. Di Carlo C., Di Spiezio Sardo A., Bifulco G., et al. Postmenopausal hypoestrogenism increases vasoconstrictor neuropeptides and decreases vasodilator neuropeptides content in arterial-wall autonomic terminations. Fertil Steril 88 (2007) 95-99
103. Kublickiene K., Svedas E., Landgren B., et al. Small artery endothelial dysfunction in postmenopausal women: In vitro function, morphology, and modification by estrogen and selective estrogen receptor modulators. J Clin Endocrinol Metab 90 (2005) 6113-6122
104. Rupnow H., Phernetton T., Shaw C., et al. Endothelial vasodilator production by uterine and systemic arteries. VII. Estrogen and progesterone effects on eNOS. Am J Physiol Heart Circ Physiol 280 (2001) H1699-H1705
105. Salom J., Burguete M., Perez-Asensio F., et al. Relaxant effects of 17-beta-estradiol in cerebral arteries through Ca(22+) entry inhibition. J Cereb Blood Flow Metab 21 (2001) 422-429
106. White R., Darkow D., and Lang J. Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. Circ Res 77 (1995) 936-942
107. Teede H. Sex hormones and the cardiovascular system: Effects on arterial function in women. Clin Exp Pharmacol Physiol 34 (2007) 672-676
108. Stevenson J. HRT and the primary prevention of cardiovascular disease. Maturitas 57 (2007) 31-34
109. Berra M., Armillotta F., D'Emidio L., et al. Testosterone decreases adiponectin levels in female to male transsexuals. Asian J Androl 8 (2006) 725-729
110. Song D., Arikawa E., Galipeau D., et al. Androgens are necessary for the development of fructose-induced hypertension. Hypertension 43 (2004) 667-672
111. Reckelhoff J. Sex steroids, cardiovascular disease, and hypertension: Unanswered questions and some speculations. Hypertension 45 (2005) 170-174